BAY 2666605 是一种具有口服活性的 PDE3A 和 PDE3B 抑制剂，IC₅₀ 分别为 87 nM 和 50 nM。BAY 2666605 是一种 PDE3A-SLFN12 复合诱导剂 (WO2019025562A1; example 135)。

BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC 50 s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135).

Solid

PDE3A 87 nM (IC50) PDE3B 50 nM (IC50

BAY 2666605 (example 135) has anticancer effects, potently inhibit brain cancer(especially glioma, more specifically glioblastoma, astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML(especially erythroleucemia), lung cancer(especially NSCLC adenocarcinoma and SCLC), skin cancer(especially melanoma), oesophagus cancer (especially squamous cell carcinoma), ovarian cancer, (especially teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer. has not independently confirmed the accuracy of these methods. They are for reference only.

BAY 2666605 (5 mg/kg; p.o; twice daily) teatment shows anti-tumor efficacy in murine xenotransplantation models of human cancer. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；In solvent -80°C 6 months

[1]. Manuel ELLERMANN, et al. Dihydrooxadiazinones. WO2019025562A1.

In Vitro: DMSO : 250 mg/mL (709.66 mM; Need ultrasonic)配制储备液